Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Chambery – page 36

785 clinical trials in Chambery, France across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Chambery at a glance
785
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

785 trials in Chambery

Open in trial search

Plasma cell myeloma

Not yet recruiting

Study of ixazomib, iberdomide and dexamethasone combination in elderly patients with first relapse of multiple myeloma

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:65+ years
  • Substances:Dexamethasone
  • Sponsor:Centre Hospitalier Universitaire De Nantes

Plasma cell myeloma

Not yet recruiting

Study on Multiple Myeloma Treatment with Isatuximab, Lenalidomide, and Carfilzomib for Patients Under 66 Eligible for Stem Cell Transplant

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Carfilzomib
  • Sponsor:Intergroupe Francophone Du Myelome

Granulomatosis with polyangiitis

Not yet recruiting

Study on Rituximab, Tocilizumab, and Tofacitinib for Patients with Granulomatosis with Polyangiitis Not Responding to Standard Therapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Azathioprine
  • Sponsor:Assistance Publique Hopitaux De Paris

Lymphatic malformation

Not yet recruiting

Study on Sirolimus for Treating Cervico-facial Lymphatic Malformations in Patients with Poor Prognosis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Sirolimus
  • Sponsor:Centre Hospitalier Universitaire De Lille

Hypertrophic cardiomyopathy

Not yet recruiting

Study on Mavacamten for Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Mavacamten
  • Sponsor:Myokardia Inc.

Non-small cell lung cancer+1

Not yet recruiting

Study of SYM024, SYM023, and SYM025 in Adults with Advanced Non-Small Cell Lung Cancer (NSCLC) with High PD-L1 Expression

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Institut De Recherches Internationales Servier IRIS

Skin squamous cell carcinoma metastatic+1

Not yet recruiting

Study of INCB099280 for Patients With Advanced Cutaneous Squamous Cell Carcinoma Not Suitable for Surgery or Radiotherapy

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:INCB099280
  • Sponsor:Incyte Corp.

Colitis ulcerative

Not yet recruiting

Study on the Effectiveness of Obefazimod for Patients with Moderate to Severe Ulcerative Colitis

Investigational
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Obefazimod
  • Sponsor:Abivax

Colitis ulcerative

Not yet recruiting

Study on the Effectiveness of Obefazimod for Patients with Moderate to Severe Ulcerative Colitis

Investigational
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Obefazimod
  • Sponsor:Abivax

Breast cancer

Not yet recruiting

Study Comparing Imlunestrant with Standard Endocrine Therapy for Patients with Early ER+, HER2- Breast Cancer at Increased Risk of Recurrence

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Eli Lilly & Co.

Acute myeloid leukaemia

Not yet recruiting

Study on the Safety of Ivosidenib and Azacitidine for Adults with Newly Diagnosed IDH1m Acute Myeloid Leukemia Not Eligible for Intensive Chemotherapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Servier Affaires Medicales

Factor VIII deficiency+1

Not yet recruiting

Study on Joint Health in Hemophilia A and B Patients Using Efmoroctocog Alfa or Eftrenonacog Alfa

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Efmoroctocog Alfa
  • Sponsor:Swedish Orphan Biovitrum AB (publ)

Other cities in France

The busiest research cities in the country

All 366 cities in France

Clinical research in Chambery

What the registry says about research in the country

01 Hematologic Oncology

Innovative research focusing on multiple myeloma and various lymphomas, evaluating novel therapeutic combinations and treatment strategies.

  • Multiple Myeloma Treatments
  • Follicular Lymphoma Studies
  • Diffuse Large B-cell Lymphoma Research

Advanced trials exploring combinations of immunotherapy and targeted treatments for blood cancers.

02 Lung Cancer Research

Studies examining innovative treatments for non-small cell lung cancer, particularly focusing on immunotherapy approaches.

  • Immunotherapy Combinations
  • Elderly Patient Treatment Options
  • Novel Therapeutic Strategies

Emphasis on improving treatment outcomes through targeted and combination therapies.

03 Preventive Medicine

Research on pneumococcal vaccines and preventive treatments, including studies in specialized patient populations.

  • Vaccine Immunogenicity
  • Safety Studies
  • High-Risk Patient Groups

Focus on vaccine effectiveness during acute illness conditions.

04 Breast Cancer Studies

Clinical trials examining treatments for hormone-sensitive breast cancer, including targeted therapies and hormone treatment optimization.

  • Hormone Therapy Duration
  • Metastatic Disease Management
  • Biomarker Studies

Investigation of personalized treatment approaches based on molecular markers.

Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.